A class action lawsuit has been filed against AMC Entertainment Holdings, Inc. alleging securities fraud related to APE (Preferred Equity Units) holders. The complaint claims that AMC made materially false and misleading statements about APE holder rights, specifically regarding a technical loophole in the Certificate of Designations that excluded APE holders from receiving a special dividend issued to common shareholders after conversion on August 25, 2023. Investors who purchased APEs between August 18, 2022, and November 1, 2023, are eligible to join the case.

Pomerantz Law Firm has filed class action lawsuits against REGENXBIO Inc., AMC Entertainment Holdings, Inc., and Upstart Holdings, Inc. for alleged securities fraud and unlawful business practices. The REGENXBIO lawsuit was triggered by an FDA clinical hold on its gene therapy candidates RGX-111 and RGX-121, which caused the stock to fall 17.9% on January 28, 2026. Investors with losses are urged to contact the firm by the April 14, 2026 deadline to potentially serve as lead plaintiff.

Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, REGENXBIO Inc., and Upstart Holdings, alleging securities fraud and unlawful business practices. The AMC lawsuit specifically concerns APE preferred equity unit holders who were excluded from a special dividend following conversion to common stock due to an undisclosed loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.

Strong Easter weekend box office performance, led by The Super Mario Galaxy Movie's $195 million domestic haul, signals resilient consumer spending despite inflation concerns. 2026 year-to-date ticket sales have reached their highest level since before the pandemic, with AMC shares surging 11%. The article suggests box office trends could serve as a real-time economic indicator of consumer health amid macro uncertainty.

Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, NuScale Power Corporation, and uniQure N.V. The AMC lawsuit concerns alleged securities fraud related to APE (Preferred Equity Units) holders being excluded from a special dividend due to a technical loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.

Pomerantz Law Firm has filed class action lawsuits against uniQure N.V., AMC Entertainment Holdings, Inc., and NuScale Power Corporation on behalf of investors who suffered losses. The primary focus is on uniQure, which experienced a 49.34% stock price decline following FDA feedback that Phase I/II study data for its AMT-130 gene therapy may be inadequate for a Biologics License Application submission. Investors have until April 13, 2026, to request Lead Plaintiff status.

Pomerantz Law Firm has filed class action lawsuits against PomDoctor Ltd. for alleged securities fraud involving a 'pump and dump' scheme using social media impersonators. PomDoctor's stock surged from $4.00 to $6.09 before crashing 91% to $0.50 on December 10, 2025. Similar lawsuits have been filed against AMC Entertainment Holdings and NuScale Power Corporation. Investors with losses are urged to contact the firm by the April 6, 2026 deadline to potentially become lead plaintiffs.

Pomerantz Law Firm has filed class action lawsuits against Kyndryl Holdings, AMC Entertainment, and NuScale Power Corporation. Kyndryl faced a 55% stock price drop following disclosure of an SEC investigation into financial reporting and the departure of its CFO, General Counsel, and Global Controller. Investors with losses are urged to contact the firm by April 13, 2026, to potentially become lead plaintiffs.

AMC Entertainment surged over 12% on April 6, 2026, following record-breaking Easter weekend revenue. The strong performance, driven by blockbuster film premieres and high-margin concessions sales, suggests potential sustained turnaround. Analysts project 80%+ upside potential, while the 22% short interest could trigger a squeeze. The company's alignment with the 'lipstick effect' consumer trend and upcoming Q1 earnings on May 6 will be key validation points.

A class action lawsuit has been filed against AMC Entertainment Holdings, Inc. alleging securities fraud violations related to APE (Preferred Equity Units) holders. The complaint claims that AMC made materially false and misleading statements about APE holder rights, specifically regarding a technical loophole in the Certificate of Designations that excluded APE holders from receiving a special dividend issued to common shareholders on August 28, 2023. Investors who purchased APEs between August 18, 2022, and November 1, 2023, are eligible to join the case, with a lead plaintiff deadline of April 20, 2026.

A class action lawsuit has been filed against AMC Entertainment Holdings and certain officers for alleged securities law violations. The suit claims that APE (Preferred Equity Units) holders were misled about their rights, as a technical loophole in the Certificate of Designations allowed AMC to exclude APE holders from distributions after conversion to common stock on August 25, 2023. Investors who purchased APEs between August 18, 2022, and November 1, 2023, are eligible to join the case, with a lead plaintiff deadline of April 20, 2026.

A class action lawsuit has been filed against AMC Entertainment Holdings, Inc. alleging securities fraud related to APE (Preferred Equity Units) holders being excluded from a special dividend following conversion to common stock. The lawsuit claims AMC made materially false and misleading statements about APE holder rights, with a technical loophole in the Certificate of Designations that was not properly disclosed to investors. The lead plaintiff deadline is April 20, 2026.